Suppr超能文献

人乳腺癌中催乳素受体浓度与雌激素受体浓度的相关性。

Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration.

作者信息

Murphy L J, Murphy L C, Vrhovsek E, Sutherland R L, Lazarus L

出版信息

Cancer Res. 1984 May;44(5):1963-8.

PMID:6324992
Abstract

The presence of receptors for lactogenic hormones in human breast cancer tissue has been documented previously, but the relationship between the expression of these receptors and estrogen receptor (ER) status has not been adequately studied. In this report, the specificity of 125I-human growth hormone (HGH) binding in both cultured human breast cancer cell lines and tumor biopsies was studied to establish that HGH was a suitable ligand for investigating lactogenic receptor concentration in these tissues. In addition, the relationship between specific binding of 125I-HGH and ER concentration in human breast cancer was investigated. Specific 125I-HGH binding to 14 breast cancer cell lines in long term culture and to membrane preparations (microsomal and plasma membrane fractions) from 31 breast cancer biopsy specimens was examined. Human prolactin and HGH were approximately equipotent in inhibiting binding of 125I-HGH to both cultured breast cancer cell lines and to membrane preparations from breast cancer biopsy specimens. Competitive inhibition experiments using lactogenic and somatogenic hormones established that the specificity of 125I-HGH binding to breast cancer biopsy material was similar to that of cultured breast cancer cell lines and similar to that reported for subprimate lactogenic receptors. Saturable, high-affinity (Ka = 0.53 to 2.33 nM-1), low-capacity (330 to 6560 sites/cell) growth hormone binding sites were found on each of the ER-positive cell lines, whereas no specific 125I-HGH binding to ER-negative cell monolayers was detected. When all cell lines were considered, a significant linear correlation (r = 0.745, p less than 0.001) between ER and lactogenic receptor concentrations was found. Significant specific 125I-HGH binding, greater than 1% of the total radioactivity added, was detected in 20 of 31 (65%) breast tumor biopsy specimens. The mean affinity and capacity of the lactogenic receptor as measured in 8 separate membrane preparations were Ka = 0.52 +/- 0.09 (S.E.) nM-1 and 255 +/- 85 fmol/mg protein. Membrane preparations from ER-negative tumors (less than 3 fmol ER/mg cytosol protein) bound significantly less 125I-HGH than did membrane preparations from ER-positive tumor biopsies (1.22 +/- 0.44 versus 3.21 +/- 0.56%, p less than 0.05). A significant linear correlation between specifically bound 125I-HGH and ER concentration (r = 0.412, p less than 0.02) was demonstrated in the 31 breast cancer biopsy specimens studied.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

此前已有文献记载人类乳腺癌组织中存在催乳激素受体,但这些受体的表达与雌激素受体(ER)状态之间的关系尚未得到充分研究。在本报告中,研究了125I-人生长激素(HGH)在培养的人乳腺癌细胞系和肿瘤活检组织中的结合特异性,以确定HGH是研究这些组织中催乳激素受体浓度的合适配体。此外,还研究了人乳腺癌中125I-HGH特异性结合与ER浓度之间的关系。检测了125I-HGH与长期培养的14种乳腺癌细胞系以及31份乳腺癌活检标本的膜制剂(微粒体和质膜部分)的特异性结合。人催乳素和HGH在抑制125I-HGH与培养的乳腺癌细胞系以及乳腺癌活检标本的膜制剂结合方面大致具有同等效力。使用催乳激素和促生长激素进行的竞争性抑制实验表明,125I-HGH与乳腺癌活检材料的结合特异性与培养的乳腺癌细胞系相似,也与灵长类以下动物催乳激素受体的情况相似。在每个ER阳性细胞系上都发现了可饱和的、高亲和力(Ka = 0.53至2.33 nM-1)、低容量(330至6560个位点/细胞)的生长激素结合位点,而未检测到125I-HGH与ER阴性细胞单层的特异性结合。当考虑所有细胞系时,发现ER与催乳激素受体浓度之间存在显著的线性相关性(r = 0.745,p小于0.001)。在31份乳腺癌活检标本中,有20份(65%)检测到显著的125I-HGH特异性结合,大于添加总放射性的1%。在8个单独的膜制剂中测得的催乳激素受体的平均亲和力和容量分别为Ka = 0.52 +/- 0.09(标准误)nM-1和255 +/- 85 fmol/mg蛋白质。ER阴性肿瘤(小于3 fmol ER/mg胞质溶胶蛋白)的膜制剂与125I-HGH的结合显著少于ER阳性肿瘤活检的膜制剂(1.22 +/- 0.44%对3.21 +/- 0.56%,p小于0.05)。在研究的31份乳腺癌活检标本中,证明特异性结合的125I-HGH与ER浓度之间存在显著的线性相关性(r = 0.412,p小于0.02)。(摘要截短至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验